Please login to the form below

Not currently logged in
Email:
Password:

Hanmi

This page shows the latest Hanmi news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

In 2015,   J&J and Hanmi entered an alliance to develop efinopegdutide to treat diabetes and obesity, with Hanmi receiving an upfront payment of $105m for the drug. ... The deal with Hanmi builds on Merck’s existing NASH pipeline, which includes a mid

Latest news

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Hanmi (SK) / Jul 15. Boehringer Ing. (DE). Olmuntinib / Lung cancer.

  • Deal Watch September 2016 Deal Watch September 2016

    No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective

  • Deal Watch November 2015 Deal Watch November 2015

    $900m of which two were with the same company, Hanmi Pharmaceutical, a Korean public company. ... Option to co-develop/co-commercialise EU/US. 1, 560. Hanmi Pharmaceutical. Janssen Pharmaceuticals. Licence.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    750. Hanmi / Eli Lilly. Licence and collaboration. Phase 1 BTK inhibitor for treatment of lupus.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Lilly's expedition to the Far East also generated another deal this month, the licence of a phase 1 BTK inhibitor from the Korean company Hanmi for up to $690m.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics